VivoSeq
Neurology

Epilepsy Syndrome

4

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Epilepsy Syndrome is an early-stage landscape with 4 programs across 3 companies. The most active players are UCB, Immedica Pharma AB, Roche. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

UCB logo

UCB

1 program

Phase 2I

Immedica Pharma AB

1 program

ApprovedRoche logo

Roche

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical2

Sulthiame

Roche

Vena Punction

Erasmus Medical Center

Phase 1
No programs
Phase 21

Lacosamide

UCB

Phase 3
No programs
Approved1

Ganaxolone

Immedica Pharma AB

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Recruiting1 · 33%

Clinical Trials

Trial Activity

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.
Completed·UCB logoUCB·Phase 2·NCT01969851·55 enrolled
Effect of Sulthiame on EEG in Childhood Epilepsy Syndromes
Recruiting·UUniversity Hospital, Angers·N/A·NCT05885646·15 enrolled
Antibodies Causing Epilepsy Syndromes: The ACES Study.
Completed·EErasmus Medical Center·N/A·NCT02802475·582 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)